Human anti-idiotypic antibodies can be good immunogens as they target Fc receptors on antigen-presenting cells allowing efficient stimulation of both helper and cytotoxic T-cell responses

International Journal of Cancer

Volumn 92, Issue 3, 2001, Pages 414-420

  Durrant, Lindy G ^a,b   Parsons, Tina ^a   Moss, Rob ^a   Spendlove, Ian ^a   Carter, Graham ^a   Carr, Frank ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b MERCK KGAA   (Germany)

Author keywords

Anti idiotypes; Blastogenesis; Helper T cell responses; Peptides; Tumour vaccines

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CHLOROQUINE; DECAY ACCELERATING FACTOR; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 4;

ANTIGEN PRESENTING CELL; ARTICLE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DONOR; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HELPER CELL; HUMAN; IMMUNOFLUORESCENCE; IMMUNOGENICITY; LYMPHOCYTE TRANSFORMATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIGEN-PRESENTING CELLS; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MICE; RECEPTORS, FC; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES;

EID: 0035342538     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1194     Document Type: Article

References (18)

1. Efficient presentation of soluble antigen by cultured human dendritic ceils is maintained by granulocyte/Macrophage colony stimulating factor plus interleukin 4 and down regulated by tumor necrosis factor alpha
2. Type I (CD64) and type II (CD32) Fcgamma receptor-mediated phagocytosis by human blood dendritic cells
3. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I restricted antigen presentation after immune complex internalization
4. Human monoclonal anti-idiotypic antibody to the tumour associated antibody 791T/36
5. Decay accelerating factor (CD55): A target for cancer vaccines?
6. Induction of delayed-hypersensitivity to human tumor-cells with a human monoclonal antiidiotypic antibody
7. Clinical outcome of colorectal-cancer patients treated with human monoclonal antiidiotypic antibody
8. 105AD7 cancer vaccine stimulates anti-tumour helper and cytotoxic T cell responses in HLA-A1,3,24 and HLA-DR 1,3,7 colorectal cancer patients
9. Vaccine induced apoptosis: A novel clinical trial endpoint?
10. A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55
11. Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotype monoclonal antibody 105AD7
12. An idiotypic replica of carcinoembryonic antigen inducing cellular and humoral responses directed against human colorectal tumors
13. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction
14. Three dimensional structure of the human class II histocompatibility antigen HLA-DRI
15. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles
16. Contrasting efficacy of presentation by major histocompatibility complex class-I and class-II products when peptides are administered within a common protein carder, self immunoglobulin
17. Idiotypic immunisation induces immunity to mutant p53 and tumour rejection
18. Tumor idiotype vaccines. VII. Analysis and correlation of structural, idiotypic and biologic properties of protective and nonprotective Ab2